Synairgen (LON:SNG) has just announced success in a preliminary trial of treatment for Covid-19. The share price has jumped 382% on the news. The new drug in called beta interferon and is administered by an inhaler. Whilst the trial results have not been reviewed by peers, and the trial numbers are small (101 patients recruited), the market seems to like this new treatment. If the trial results are confirmed and the drug is approved for use in Covid-19, this could be good news for all drug companies that manufacture beta interferon - beta interferon has actually been around for years and is not a new product - it is the application that is new. For those of us - most of us I'd guess - who haven't got shares in Synairgen (LON:SNG) it's likely that this news will provide a boost to the whole pharmaceutical and biotech sector. DYOR.

Unlock this Article with a 14 day free trial

or Unlock with your email

Already have an account?
Login here